These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28688124)

  • 61. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
    Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
    Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
    Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
    Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
    Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
    Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.
    Nomura M; Shitara K; Kodaira T; Hatooka S; Mizota A; Kondoh C; Yokota T; Takahari D; Ura T; Muro K
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):946-52. PubMed ID: 21362578
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
    Michal SA; Adelstein DJ; Rybicki LA; Rodriguez CP; Saxton JP; Wood BG; Scharpf J; Ives DI
    Head Neck; 2012 Aug; 34(8):1147-52. PubMed ID: 22021098
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
    Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
    Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Planned post-chemoradiation neck dissection: significance of radiation dose.
    Stenson KM; Huo D; Blair E; Cohen EE; Argiris A; Haraf DJ; Vokes EE
    Laryngoscope; 2006 Jan; 116(1):33-6. PubMed ID: 16481805
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
    Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
    Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Matched cohort analysis of the effect of pretreatment positron emission tomography on clinical outcomes of patients with head and neck cancer treated with definitive chemoradiotherapy.
    Fried D; Khandani A; Shores C; Weissler M; Hayes N; Hackman T; Rosenman J; Chera BS
    Head Neck; 2012 Mar; 34(3):412-7. PubMed ID: 21853498
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
    Araki D; Redman MW; Martins R; Eaton K; Baik C; Chow L; Goulart B; Lee S; Santana-Davila R; Liao J; Parvathaneni U; Laramore G; Futran N; Mendez E; Bhrany A; Rodriguez CP
    Head Neck; 2016 Sep; 38(9):1318-23. PubMed ID: 27061333
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of concomitant chemotherapy on outcomes of radiation therapy for head-and-neck cancer: a population-based study.
    Gupta S; Kong W; Booth CM; Mackillop WJ
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):115-21. PubMed ID: 24331657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nuclear NF-κB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy.
    Balermpas P; Michel Y; Wagenblast J; Seitz O; Sipek F; Rödel F; Rödel C; Fokas E
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):785-90. PubMed ID: 23664323
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma.
    Singh B; Bhaya M; Zimbler M; Stern J; Roland JT; Rosenfeld RM; Har-El G; Lucente FE
    Head Neck; 1998 Jan; 20(1):1-7. PubMed ID: 9464945
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Restaging PET-CT after radiochemotherapy can spare patients with advanced head and neck cancer from neck dissection provided they are in complete remission].
    Hermann RM; Christiansen H
    Strahlenther Onkol; 2016 Aug; 192(8):589-91. PubMed ID: 27315088
    [No Abstract]   [Full Text] [Related]  

  • 78. Induction chemotherapy followed by radiochemotherapy for locally advanced head and neck cancer as an individual treatment approach-Feasibility, safety and retrospective survival analysis in twenty-three patients.
    Busch CJ; Girke J; Tribius S; Bussmann L; Knecht R; Schafhausen P; Lörincz BB; Münscher A
    Clin Otolaryngol; 2017 Dec; 42(6):1392-1396. PubMed ID: 28429525
    [No Abstract]   [Full Text] [Related]  

  • 79. Results of concurrent radio-chemotherapy for the treatment of head and neck squamous cell carcinoma in everyday clinical practice with special reference to early mortality.
    Schlumpf M; Fischer C; Naehrig D; Rochlitz C; Buess M
    BMC Cancer; 2013 Dec; 13():610. PubMed ID: 24373220
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy.
    Cannon DM; Geye HM; Hartig GK; Traynor AM; Hoang T; McCulloch TM; Wiederholt PA; Chappell RJ; Harari PM
    Head Neck; 2014 Aug; 36(8):1120-5. PubMed ID: 23804248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.